RNA polymerase I transcription machinery (Pol I machinery) (Pol I machinery)

The RNA polymerase I (Pol I) transcription machinery is a specialized multi-protein complex dedicated to the synthesis of the 45S precursor ribosomal RNA (rRNA), which is the rate-limiting step in ribosome biogenesis (Hannan et al., 2013, Nat Rev Drug Discov). This machinery consists of the 14-subunit Pol I enzyme and essential regulatory factors like the Upstream Binding Factor (UBF) and the Selectivity Filter 1 (SL1) complex (Drygin et al., 2010, Annu Rev Pharmacol Toxicol). In malignant cells, Pol I activity is frequently hyperactivated to support the high protein synthesis demands of rapid proliferation, making it a compelling target for cancer therapy (Bywater et al., 2012, Cancer Cell). Therapeutic agents such as CX-5461 and BMH-21 are designed to selectively inhibit Pol I-driven transcription, thereby inducing nucleolar stress and activating p53-dependent or independent cell death pathways (Peltonen et al., 2014, Cancer Cell). Beyond oncology, genetic mutations in Pol I components are linked to ribosomopathies like Treacher Collins syndrome, which is characterized by craniofacial developmental defects (Dauwerse et al., 2011, Nat Genet). Understanding the regulation of this machinery is crucial for developing selective inhibitors that can effectively treat cancer while minimizing systemic toxicity.

Other names

RNA polymerase I complexPol I transcription apparatusRibosomal DNA transcription machineryPol I system

The primary mechanism involves the selective inhibition of ribosomal RNA (rRNA) synthesis. Drugs like CX-5461 prevent the assembly of the Pol I initiation complex by blocking the interaction between the SL1 transcription factor and the rDNA promoter (Drygin et al., 2011, Cancer Res). Other agents, such as BMH-21, bind to GC-rich rDNA sequences and trigger the proteasome-mediated degradation of the RPA190 catalytic subunit of the Pol I enzyme (Peltonen et al., 2014, Cancer Cell). This disruption leads to nucleolar stress, which stabilizes p53 and induces apoptosis in cancer cells (Hannan et al., 2013, Nat Rev Drug Discov).